Human iPS Cell Line (Retroviral)
Catalog# | Unit | Unit Price (USD) | Actions |
---|---|---|---|
iPS01 | 5x105 cells/vial | $1,081.00 | Add to Cart |
Highlights:
human iPS01 cell lines generated by retroviral transduction are ideally suited for various research purpose including 1) differentiating various somatic cells or organoid models for phenotypic and target-based compound screening, 2) establishing genetically modified disease model through CRISPR/Cas9 editing, and 3) generating functional cells/tissues as regenerative biology initiatives. iPS01 has several features such as:
- Low passage and long-term viability
- Off the shelf - simple thaw the cells and plate them onto serum-free, feeder-free culture
- Homogeneity– Originated from a single iPSC clone
Description:
Human iPS (induced pluripotent stem) cell line (cat # iPS01) was derived from human foreskin fibroblasts (HFFs) by retroviral expression of OCT4, SOX2, KLF4, and c-MYC genes. The cells were derived using morphological selection criteria and without the use of fluorescent marker or drug selection. When cultured under standard human ES cell culture conditions, the morphology of human iPS cells are identical to that of human ES cells. The cells also express the pluripotency markers SSEA-4 and Nanog, and demonstrate strong endogenous alkaline phosphatase.
Specifications:
Product Name | Human iPS Cell Line (Retroviral) |
---|---|
Shipping Condition |
Dry Ice - Overnight Shipping |
Storage and Stability |
Store in vapor phase of liquid nitrogen immediately upon receipt. This product is stable for 6 months when stored as directed. |
Quality Control | Human iPS cells were grown in human ES medium supplemented with 10 ng/ml of bFGF. Each lot of human iPS cells is tested for growth and viability following recovery from cryopreservation. In addition, each lot is tested for expression of SSEA-4 and Nanog, as well as the activity of alkaline phosphatase. |
Restricted Use |
For Research Use Only. Not for use in diagnostic or therapeutic procedures. |
Clinical Applications of Induced Pluripotent Stem Cells – Stato Attuale Cell Biology and Translational Medicine (2018)